NCT06285448
Feasibility of Lecanemab Registry and Clinical Outcome Measures
Enrolling by Invitation
Not specifiedAges 18+ObservationalHealthPartners InstituteInvestigator-initiated
~20 participants
Updated 2026-01-28 on ClinicalTrials.gov
What's tested:Lecanemab
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of enrollment
Measured over 2 years
+3 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Bhavani Kashyap, MBBS, PhD · PRINCIPAL_INVESTIGATOR · HealthPartners Institute
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
PLWD who are eligible to receive Lecanemab infusion at our clinics.
Care Partner who provides care for the PLWD who are eligible to receive Lecanemab infusion at our clinics.
Age \>=18 years for PLWD and their care partners
Provides informed consent prior to participation.
Exclusion
Unable to read and speak English
What this trial measures
- Feasibility of enrollment2 years
Absolute number of potential care dyads (care partners and people living with dementia) contacted for recruitment and the number of those who consent and enroll.
- Feasibility of completing visits3 months
Number of enrolled participants completing the baseline and visit at 3 months.
- Qualitative experience at 3 months3 months
Summary of qualitative experience with lecanemab infusions at 3 months through survey and interviews .
- Qualitative experience at 12 months12 months
Summary of qualitative experience with lecanemab infusions at 12 months through survey and interviews .